Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion type Assertion NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_head.
- NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion description "[Serum ANXA2 expression in HCC patients was correlated with HBV infection (27.38 � 5.67 ng/mL vs 18.58 � 7.83 ng/mL, P < 0.01), extrahepatic metastasis (26.11 � 5.43 ng/mL vs 22.79 � 5.64 ng/mL, P < 0.01), and portal vein thrombus (26.03 � 5.99 ng/mL vs 23.06 � 5.03 ng/mL, P < 0.01), and was significantly higher (P < 0.01) in the moderately- (26.19 � 5.34 ng/mL) or the poorly- differentiated group (27.05 � 5.13 ng/mL) than in the well differentiated group (20.43 � 4.97 ng/mL), and in the tumor node metastasis stages III-IV (P < 0.01) than in stages?I-II.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_provenance.
- NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion evidence source_evidence_literature NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_provenance.
- NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion SIO_000772 23139605 NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_provenance.
- NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion wasDerivedFrom befree-2016 NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_provenance.
- NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_assertion wasGeneratedBy ECO_0000203 NP1027204.RA2p8L5xvYFa3Fsc5WwCZDwpclpr5mfwBNFoPwOSjZ3hY130_provenance.